Neumora Therapeutics, Inc. (NMRA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$147.1M
Cash & Equivalents
$46.4M
Quarterly Burn Rate
10 mo
Est. Cash Runway
$311M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06029439 | Study to Assess the Safety and Effectiveness of NMRA-335140-501 | PHASE3 | Active Not Recruiting | 1,000 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-15 | 8-K | Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522) - EX-99.1 | EDGAR |